| Enfortumab vedotin–related cutaneous toxicity and radiographic response in patients with urothelial cancer: A single-center experience and review of the literature E Vlachou, A Matoso, D McConkey, Y Jing, BA Johnson 3rd, NM Hahn, ... European Urology Open Science 49, 100-103, 2023 | 11 | 2023 |
| Polymer-coated paclitaxel-eluting stents for the treatment of stenosed native arteriovenous fistulas: long-term results from the ELUDIA study K Katsanos, P Ho, TY Tang, E Vlachou, CJQ Yap, PM Kitrou, ... The Journal of Vascular Access, 11297298231174263, 2023 | 3 | 2023 |
| Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience. E Vlachou, NM Hahn, A Dabb, BA Johnson, MS Lefande, ... Journal of Clinical Oncology 41 (6_suppl), 523-523, 2023 | 3 | 2023 |
| Frontline immune checkpoint inhibitors in patients≥ 90 years with advanced urothelial cancer: a single center experience. E Vlachou, ⅢBA Johnson, E Guancial, KA Lombardo, J Hoffman-Censits The Canadian Journal of Urology 31 (3), 11875-11879, 2024 | | 2024 |
| Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer E Vlachou, BA Johnson III, E Baraban, R Nadal, J Hoffman-Censits American Society of Clinical Oncology Educational Book 44 (3), e438640, 2024 | | 2024 |
| Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin E Vlachou, R Mamtani, NM Hahn, B Johnson III, J Hoffman-Censits, ... Clinical Genitourinary Cancer 22 (3), 102090, 2024 | | 2024 |
| Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts. E Vlachou, R Mamtani, NM Hahn, BA Johnson, JH Hoffman-Censits, ... Journal of Clinical Oncology 42 (4_suppl), 544-544, 2024 | | 2024 |
| Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience. E Vlachou, BA Johnson, R Elias, NM Hahn, DJ McConkey, ... Journal of Clinical Oncology 42 (4_suppl), 569-569, 2024 | | 2024 |
| Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC). E Vlachou, R Elias, NM Hahn, DJ McConkey, BA Johnson, ... Journal of Clinical Oncology 42 (4_suppl), 570-570, 2024 | | 2024 |
| Evaluating outcomes of sacituzumab govitecan (SG) in patients with urothelial cancer (UC), previously treated with enfortumab vedotin (EV). E Vlachou, BA Johnson, NM Hahn, K Rourke, DJ McConkey, ... Journal of Clinical Oncology 42 (4_suppl), 567-567, 2024 | | 2024 |
| Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience E Vlachou, BA Johnson 3rd, D McConkey, Y Jing, A Matoso, NM Hahn, ... Frontiers in Oncology 14, 2024 | | 2024 |
